- Home
- TVTX vs BYD Comparison
TVTX vs BYD Comparison
Compare TVTX & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | BYD |
|---|---|---|
| Founded | N/A | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TVTX | BYD |
|---|---|---|
| Price | $62.14 | $84.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | $40.62 | ★ $90.82 |
| AVG Volume (30 Days) | ★ 1.6M | 978.2K |
| Earning Date | 05-04-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | 92.89 | ★ 264.46 |
| EPS | N/A | ★ 3.12 |
| Revenue | N/A | ★ $2,626,730,000.00 |
| Revenue This Year | $44.76 | $1.71 |
| Revenue Next Year | $35.51 | $2.74 |
| P/E Ratio | ★ N/A | $26.67 |
| Revenue Growth | N/A | ★ 9.41 |
| 52 Week Low | $17.05 | $76.33 |
| 52 Week High | $66.24 | $91.41 |
Technical Indicators
Market Signals| Indicator | TVTX | BYD |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 44.47 |
| Support Level | $53.76 | $80.67 |
| Resistance Level | $66.24 | $87.08 |
| Average True Range (ATR) | 2.59 | 2.00 |
| MACD | 0.27 | -0.35 |
| Stochastic Oscillator | 67.32 | 26.47 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.